


Catalog# BP-50169

Ado-Trastuzumab emtansine (KADCYLA®)

Description:

Ado-Trastuzumab emtansine (KADCYLA®) is a HER2-targeted antibody-drug conjugate (ADC) which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 (a maytansine derivative) via the stable thioether linker MCC (4-[N-maleimidomethyl] cyclohexane1-carboxylate). Emtansine refers to the MCC-DM1 complex. The antibody trastuzumab, is a well characterized recombinant monoclonal antibody product produced by mammalian (Chinese hamster ovary) cells, and the small molecule components (DM1 and MCC) are produced by chemical synthesis. Ado-trastuzumab emtansine contains an average of 3.5 DM1 molecules per antibody. This product is used for research only. It can be used as a reference compound. Ado-trastuzumab emtansine has the following chemical structure:



Note: The bracketed structure is DM1 plus MCC which represents the emtansine component. The n is, on average, 3.5 DM1 molecules per trastuzumab (Mab) molecule.

Product Details	
Species Reactivity	Human
Published Species	Human
Host/Isotype	Cell culture/ IgG1
Class	Monoclonal
Type	Antibody-drug conjugate
Clone	Trastuzumab biosimilar
Conjugate	Trastuzumab conjugated with SMCC-DM1
DAR	~ 3.5
Immunogen	Human Her2
Form	Liquid
Concentration	1 mg/ml
Purification	Size exclusive column
Storage buffer	50 mM Sodium Phosphate, 0.05% Tween-20, pH7.4
Storage conditions	4°C for short time, -20°C or -80°C for long time.